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ABSTRACT
Understanding of the pathophysiology of cholestasis associated carcinogenesis 
could challenge the development of new personalized therapeutic approaches and 
thus improve prognosis. Simultaneous damage might aggravate hepatic injury, induce 
chronic liver disease and even promote carcinogenesis. We aimed to study the effect 
of Hepatitis B virus surface protein (HBsAg) on cholestatic liver disease and associated 
carcinogenesis in a mouse model combining both impairments. Hybrids of Abcb4-/- 
and HBsAg transgenic mice were bred on fibrosis susceptible background BALB/c. 
Liver injury, serum bile acid concentration, hepatic fibrosis, and carcinogenesis were 
enhanced by the combination of simultaneous damage in line with activation of c-Jun 
N-terminal kinase (JNK), proto-oncogene c-Jun, and Signal transducer and activator of 
transcription 3 (STAT3). Activation of Protein Kinase RNA-like Endoplasmic Reticulum 
Kinase (PERK) and Eukaryotic translation initiation factor 2A (eIF2α) indicated unfolded 
protein response (UPR) in HBsAg-expressing mice and even in Abcb4-/- without 
HBsAg-expression. CONCLUSION: Cholestasis-induced STAT3- and JNK-pathways 
may predispose HBsAg-associated tumorigenesis. Since STAT3- and JNK-activation 
are well characterized critical regulators for tumor promotion, the potentiation of their 
activation in hybrids suggests an additive mechanism enhancing tumor incidence.
INTRODUCTION
Various phenotypes of chronic liver disease like 
progressive familial intrahepatic cholestasis (PFIC type 3) 
or biliary liver cirrhosis have been attributed to mutations 
of the human ABCB4 gene [1]. The ABCB4 gene encodes 
the P-glycoprotein ABCB4, a member of the ATP-binding 
cassette (ABC) transporters, which is responsible for 
phospholipid transport across the canalicular membrane. 
ABCB4 harbors numerous missense mutations which 
probably reflect the spectrum of liver disease depending on 
ABCB4 background [2]. The lack of Abcb4 transporters 
in mice causes a complete absence of micelle forming 
phospholipids from bile, which results in liver injury from 
chronic cholangitis [3]. Abcb4 knockout mice (Abcb4-/-) 
represent a highly reproducible, well characterized non-
surgical mouse model for cholangiopathy [3].
Hepatic injury in patients with chronic hepatitis B 
virus (HBV) infection has mainly been attributed to T cell 
response against infected hepatocytes [4, 5]. Nevertheless, 
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observations in HBV infected patients under conditions 
of immune suppression and in transgenic mouse models 
of HBV infection suggest, that cellular modifications 
induced by HBsAg proteins may also lead to liver 
disease in the absence of adaptive immune responses 
[6–8]. In HBV infected humanized uPA-SCID chimeric 
mice the majority of human hepatocytes had ground-
glass appearance, stained intensely for viral proteins, and 
showed considerable hepatic damage and cell death [6]. 
Interestingly, transgenic mice expressing HBV surface 
proteins demonstrated comparable histopathologic 
pattern including inflammation, regenerative hyperplasia, 
transcriptional deregulation, aneuploidy progressing to 
neoplasia, and even hepatocellular carcinoma (HCC) 
[6, 9–11]. Underlying pathomechanisms are based on 
hepatic accumulation of HBsAg inducing ER stress and 
subsequent activation of UPR [10–12]. HBsAg transgenic 
mice (HBsAg+/-) are largely tolerant towards transgenic 
proteins [13] and thus represent an excellent model for 
the investigation of direct cytotoxic effects of HBsAg 
and protein storage disease [11, 14, 15]. A higher HBsAg 
level can predict disease progression [16]. HBsAg is 
an important predictor of hepatocellular carcinoma 
(HCC) in patients with chronic HBV infection as 
hepatocarcinogenesis is predominantly observed in patients 
with high HBsAg levels [17]. Furthermore, Trierweiler et 
al. demonstrated that the transcription factor c-JUN/AP-1 
promotes HCC in HBsAg-transgenic mice [18].
Additionally, it has been suggested that the 
accumulation of a misfolded protein in the liver can 
sensitize to other injuries [19]. The aim of this study was 
to characterize aggravation of cholestatic liver disease and 
carcinogenesis by HBsAg expression in Abcb4-/--mice. We 
hypothesized that hepatic expression of HBsAg in mice 
lacking the phospholipid flippase multidrug resistance 
protein 2 (Abcb4-/-) represents a suitable model to analyze 
simultaneous damage by direct cytopathic effects of 
HBsAg and chronic biliary liver disease. In this study, 
we established a murine HBsAg+/-/Abcb4-/-- model and 
characterized mechanisms leading to enhanced liver injury 
and carcinogenesis.
RESULTS
Elevated liver injury in Abcb4-/-/HBsAg+/- mice
Abcb4-/-/HBsAg+/- mice demonstrated age related 
increasing infiltration of immune cells in portal fields 
compared with controls (Figure 1A). Significant 
destruction of liver architecture and pronounced localized 
compensatory proliferation were most prominent in the 
liver of Abcb4-/-/HBsAg+/- animals. Proliferation of bile 
ducts in Abcb4-/- mice was enforced by HBsAg expression 
in Abcb4-/-/HBsAg+/- mice. Serum ALT was significantly 
increased in all transgenic mice. Levels increased 2-3-fold 
in Abcb4-/-/HBsAg+/- animals in comparison to Abcb4-/- 
controls (Figure 1B). Moreover, ALT in Abcb4-/-/HBsAg+/- 
mice nearly reflects the sum of ALT levels in Abcb4-/- and 
HBsAg+/- controls. During the observation period, serum 
ALT levels raised from 521 U/L at the age of 7-8 weeks 
up to 920 U/L in 52 weeks old Abcb4-/-/HBsAg+/- animals.
Reduced HBsAg expression in Abcb4-/-/HBsAg+/- 
mice did not influence UPR
In order to compare hepatic transgene accumulation in 
HBsAg+/-- and Abcb4-/-/HBsAg+/- mice, HBsAg was analyzed 
by Western blotting and immunohistochemistry (Figures 
1C and 1D). Western blotting revealed expression of large 
(LHBsAg) and small (SHBsAg) HBsAg. Neither LHBsAg 
nor SHBsAg expression was found in wild type and Abcb4-/- 
mice. HBsAg expression was reduced in Abcb4-/-/HBsAg+/- 
mice compared to HBsAg+/- controls at ages of 12-16 
weeks and 52 weeks. Hepatic accumulation of HBsAg was 
stronger in male than in female transgenic mice. A reduction 
of transgene expression was observed in female and male 
Abcb4-/-/HBsAg+/- mice in comparison to HBsAg+/- controls 
(Figure 1C and 1D). Immunostaining demonstrated HBsAg 
accumulation in all hepatocytes of Abcb4-/-/HBsAg+/- mice. 
The amount of intracellular HBsAg, however, was reduced 
in comparison to HBsAg+/- control mice (Figure 1D) negative 
controls for the staining of HBsAg in wild type mice and 
Abcb4-/- mice shown in Supplementary Figure 1. In order 
to investigate the effect of cholestasis on HBsAg-associated 
ER stress [11, 12], activation of GRP78, PERK, eIF2a, and 
Chop was analyzed by Western blotting. Phosphorylation 
of PERK, eIF2α, and ER stress induced GRP78 and 
CHOP expression were similar in Abcb4-/-/HBsAg+/- mice 
compared with HBsAg+/- mice (Figure 1C). Interestingly, 
GRP78, PERK and eIF2α were also activated in 
Abcb4-/- mice. This effect was most prominent in 52 weeks 
old mice. Nevertheless, expression of CHOP was missing in 
Abcb4-/- controls.
Serum bile acid concentrations were potentiated 
in Abcb4-/-/HBsAg+/- mice
Serum concentrations of 11 analyzed Taurine 
conjugates were combined to illustrate the global increase 
in serum bile acid concentrations in Abcb4-/-/HBsAg+/- 
(Figure 2A). Bile acid concentrations were also enhanced 
in HBsAg transgenic mice in comparison to wild type 
controls aged 52 weeks (#p=0.001). Unconjugated bile 
acids and glycine conjugates were detected at negligible 
levels and thus were excluded from further analysis. 
Interestingly, relative serum levels of TUDCA, a 
protective bile acid, were significantly reduced in Abcb4-
/-/HBsAg+/- mice (Figure 2B). Serum ALT and bile acid 
concentrations correlated well, even in HBsAg+/- controls 
(Figure 2C and 2D). Figure 2E and 2F demonstrate the 
absolute- and relative composition of the 8 most abundant 
bile acids in serum. Complete data of all bile acids are 
presented in Supplementary Table 1.
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HBsAg expression increased fibrosis and biliary 
proliferation in Abcb4-/-/HBsAg+/- mice
Fibrotic fibers were visualized by Sirius red (SR) 
staining (Figure 3A). Onion-skin-like periductular 
fibrosis already developed in young Abcb4-/- and Abcb4-/-
/HBsAg+/- mice. The gain of periportal and septal fibrosis 
characterized progressive fibrosis in Abcb4-/-/HBsAg+/- 
mice. Quantification of the SR-stained area of the tissue 
revealed significant fibrosis in liver injury models at all 
ages (Figure 3B). Abcb4-/-/HBsAg+/- mice aged 12-16 
week showed enhanced fibrosis compared to controls 
(wild type: 0.24±0.09%, Abcb4-/- 0.90±0.58%, HBsAg+/- 
0.57±0.16%, and Abcb4-/-/HBsAg+/- 1.19±0.58%). Glial 
fibrillary acidic protein (GFAP)- and desmin positive 
cells appeared more frequently in Abcb4-/-/HBsAg-/- 
Figure 1: HBsAg expression elevates liver injury in Abcb4 knockout mice. A. Liver histology demonstrates accelerated 
portal inflammation and pronounced bile duct disease in Abcb4-/-/HBsAg+/- mice. Magnification x200, scale bars 100 μm. B. HBsAg 
expression increases serum ALT in Abcb4-/- mice. Open bars represent wild types, light grey bars Abcb4-/-, dark grey bars HBsAg+/-, and 
black bars Abcb4-/-/HBsAg+/-. C. Western blotting demonstrates reduced expression of HBsAg and ER stress in Abcb4-/-/HBsAg+/- mice. D. 
Immunohistochemistry visualizes reduced HBsAg expression in female Abcb4-/-/HBsAg+/- mice. Representative micrographs are shown.
Oncotarget52563www.impactjournals.com/oncotarget
mice, especially around portal tracts (Figure 3C), 
indicating enhanced activation of hepatic stellate cells. 
Immunostaining for SOX9 (biliary marker) indicated 
ductular reaction in Abcb4-/- mice (arrows Figure 3C). 
Furthermore, SOX9+ cells of hepatocyte shape indicated 
the participation of chronically injured hepatocytes within 
ductular reactions in Abcb4-/-- and Abcb4-/-/HBsAg+/- mice 
(arrowheads Figure 3C) [20, 21].
Abcb4-/-/HBsAg+/- mice display enhanced 
carcinogenesis
Hepatic tumors were observed in 8 out of 9 
Abcb4-/-/HBsAg+/- mice aged 52 weeks (Ø=8.3±4.5 
mm) whereas in Abcb4-/- controls only 1 out of 9 
animals (Ø=2mm) developed tumors (Figure 4A 
and 4B). Hence, development of hepatic tumors in 
Figure 2: Total serum BA levels raise while relative amount of protective BAs decrease in Abcb4-/-/HBsAg+/- mice. A. 
Total serum taurine conjugated Bas (T-BAs) increased in Abcb4-/-/HBsAg+/--mice in comparison to controls. Serum T-BAs were measured 
by UHPLC-MS/MS at the day of sacrifice. Total T-BAs are depicted. Note, total T-BAs were increased in Abcb4-/--mice in comparison 
to wt controls and in HBsAg+/- transgenic mice aged 52 weeks as well (#). B. Relative amount of protective TUDCA was decreased in 
Abcb4-/-/HBsAg+/--mice. Results are presented as means ± SEM, n=4-10. *p<0.05 as indicated, #p=0.001 in comparison to wt control. Open 
bars represent wild types, light grey bars Abcb4-/-, dark bars HBsAg+/-, and black bars Abcb4-/-/HBsAg+/-. C. Scatter-plot demonstrates the 
correlation of ALT and total serum T-BA levels. All data of 52 week old animals are included; open dots wt, grey dots Abcb4-/-, dark grey 
dots HBsAg+/-, black dots Abcb4-/-/HBsAg+/-. D. Scatter-plot demonstrates the correlation of ALT and total serum T-BA levels in HBsAg+/--
mice. E and F. Absolute- (E) and relative (F) composition of the 8 most abundant bile acids in serum.
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Abcb4-/-/HBsAg+/- animals was significantly increased 
by HBsAg expression in comparison to Abcb4-/- controls 
(Χ2=10.9, p=0.001). Increased tumor size went along 
with pronounced angiogenesis in Abcb4-/-/HBsAg+/- mice 
(Figure 4A, lower right panel). We recently described 
tumorigenesis in HBsAg+/- controls (58% of male and 
0% of female HBsAg+/- mice aged 52 weeks) [11]. 
Neither wild type mice nor young mice developed any 
tumors at all.
In order to characterize signaling pathways 
promoting hepatic tumor growth, phosphorylation of 
c-Jun, c-Jun N-terminal kinase (JNK), as well as STAT-3 
were analyzed by Western blot analysis of hepatic protein 
extracts. c-Jun expression as well as c-Jun phosphorylation 
were enhanced in Abcb4-/-/HBsAg+/- mice suggesting 
cumulative effects of both murine models (Figure 4C). 
In addition, activation of JNK was enhanced in Abcb4-/-
/HBsAg+/- mice compared to controls. STAT3 activation 
was stronger in Abcb4-/- mice in comparison to HBsAg+/- 
controls and appeared with nearly additive signal 
intensities in Abcb4-/-/HBsAg+/- mice.
Histologically, tumors were characterized by a 
defined tumor border (Figure 5A), lack of fibrillary 
collagen (Figure 5B), remarkable cellular proliferation 
(Figure 5C), lack of type IV collagen in the tumor 
parenchyma (Figure 5D), diffuse glutamine synthetase 
expression pattern (Figure 5E), and a lack of HBsAg 
expression (Figure 5F).
DISCUSSION
In the present study two well characterized murine 
models of liver injury have been combined in order 
to elucidate the interplay of cholestasis and HBsAg 
induced tumorigenesis [11, 18, 22, 23]. The extent of 
liver damage, cholestasis, and fibrosis was enhanced in 
Abcb4-/-/HBsAg+/- mice. Activation of proto-oncogene 
c-Jun, transcription factor STAT3, and tumorigenesis 
were even potentiated by simultaneous damage. This is the 
first time that a ‘second hit’ mouse model for genetically 
determined cholestasis and HBsAg-induced liver damage 
generating carcinogenesis has been described.
Figure 3: Hepatic fibrosis is elevated in Abcb4-/-/HBsAg+/- mice. A. Representative Sirius red staining demonstrates enhanced 
collagen accumulation in Abcb4-/-/HBsAg+/- mice. Magnification x100, scale bars 200 μm. B. Quantification of SiriusRed positive area was 
performed by computer-analysis (ImageJ). Open bars represent wild types, light grey bars Abcb4-/-, dark grey bars HBsAg+/-, and black bars 
Abcb4-/-/HBsAg+/-. C. HBsAg expression enhanced HSC activation and ductular reaction. Representative immunohistochemical stainings 
for quiescent HSC marker GFAP, HSC activation marker desmin, and transcription factor SOX9 in 12-16 week old mice. Magnification 
x100, scale bars 100μm. Results are presented as means ± SEM, n=6-10. *p<0.05 as indicated.
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Remarkably, the current study demonstrates 
aggravation of liver disease by intracellular HBsAg 
accumulation without viral infection in case of 
simultaneous labefaction. Primary biliary fibrosis 
and biliary atresia with additional HBV infection has 
been described in clinical studies [24, 25]. In addition, 
biliary diseases might even be attributed or caused 
by HBV infection [26, 27]. Especially, patients with 
immunosuppression and chronic HBV infection are at 
high risk of developing fibrosing cholestatic hepatitis, an 
aggressive and mostly fatal form of viral hepatitis [14]. 
Our data strengthen the idea that intracellular HBsAg 
accumulation might contribute to the aggravation of HBV 
associated cholestasis.
In 1998, a so called ‘two hit’ theory proposed 
steatosis as first hit sensitizing liver tissue to a 
variety of second hits like oxidative stress leading to 
necroinflammation and fibrosis [28]. With regard to our 
current results, HBsAg induced storage disease might 
be considered as a ‘second-hit’ providing the potential 
to enforce carcinogenesis in simultaneous chronic liver 
damage. This hypothesis is strengthened by the fact that 
patients with high HBV surface antigen levels develop 
HCC dose dependently [16, 17].
Increased ALT activity in Abcb4-/-/HBsAg+/- mice 
nearly reflects the sum of individual ALT levels in 
corresponding transgenic/knock out controls and thus 
suggests an additive effect of both liver diseases. Liver cell 
Figure 4: Induction of carcinogenic pathways enhanced tumor incidence in Abcb4-/-/HBsAg+/- mice. A. Macroscopic view 
of well vascularized primary tumors > 5mm in diameter which appeared more frequently in Abcb4-/-/HBsAg+/- mice. B. Tumor diameter is 
shown in Box and Whisker Plots. Enhanced incidence was calculated with Chi2 statistics. The upper and lower hinges of the box represent 
the 75th and 25th percentile, respectively. The line indicates the median value; error bars represent the minimum and maximum. C. 
Western blot analysis of phospho-SAPK/JNK (P-JNK), β-actin, phospho-c-Jun (P-cJun), c-Jun, phospho-STAT3 (P-STAT3), and STAT3 
demonstrate enhanced induction of carcinogenic pathways in Abcb4-/-/HBsAg+/- mice.
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damage, caused by a lack of Abcb4-transporters is primarily 
localized to the periportal area due to regurgitation of bile 
acids from leaky bile ducts whereas in HBsAg+/- mice liver 
cell damage is homogenously distributed throughout the 
whole lobules. From the histopathological point of view 
cumulation of these damages might be possible. These 
findings correlate with enhanced cholangitis/pericholangitis 
and bile duct proliferation. Interestingly, serum bile salt 
concentrations correlate with serum ALT. It has been 
shown recently that serum bile acid concentrations >10 
μM caused hepatocellular damage reflected by enhanced 
ALT levels [29]. Furthermore, BAs may behave as 
cancer promoters through indirect mechanisms involving 
oxidative stress and DNA damage, as well as they can 
act as selection agents for apoptosis-resistant cells [30]. 
On the other hand, tauroursodeoxycholic acid (TUDCA) 
protects hepatocytes from bile acid-induced apoptosis 
via activation of survival pathways [31]. Another 
study demonstrated that unconjugated UDCA provides 
protection against the cytotoxicity due to toxic BAs, the 
stimulation of hepatobiliary secretion, antioxidant activity, 
due in part to an enhancement in glutathione levels, and 
the inhibition of liver cell apoptosis [30]. It has been 
demonstrated that bile acids can induce endoplasmic 
reticulum stress, which in turn stimulates apoptosis, in 
a hydrophobicity dependent manner [32]. On the other 
hand it has been suggested that ER-stress can alter bile 
acid metabolism [33]. The absolute amount of TUDCA is 
unchanged but the relative amount of TUDCA decreased 
by the total increase of BAs (Supplementary Table 1). 
Nevertheless, the absolute increase of BAs might be a 
cumulative effect of enhanced BA-concentrations in 
both models (Figure 2) and of ER-stress-altered BA-
metabolism [33]. According to these observations, reduced 
TUDCA levels in Abcb4-/-/HBsAg+/- mice presumably 
contributed to deleterious effects of enhanced serum 
bile acid concentrations. The current data suggest that 
the combination of the underlying biliary components 
of individual damage might critically influence the 
exacerbation of pathologic effects in Abcb4-/-/HBsAg+/- 
mice.
Beyond the finding, that a combination of murine 
models caused a cumulative effect on hepatocellular 
damage and fibrosis, development of hepatic tumors 
was potentiated in Abcb4-/-/HBsAg+/- mice. In contrast to 
human beings, where HCC development is mostly based 
on hepatic cirrhosis, Abcb4-/-/HBsAg+/- mice displayed a 
high tumor development without underlying cirrhosis. In 
HBV infection, the risk of HCC development is primary 
linked to cirrhosis, as HCC incidence rises from 0.6 per 
100 persons in chronic HBV infected patients without 
cirrhosis to 3.7 in HBV cirrhosis [17, 34]. JNK, c-JUN, 
and STAT-3 activation were pronounced in Abcb4-/-/
HBsAg+/- mice (Figure 4C). JNK- as well as downstream 
c-Jun-, and STAT-3-activation mediate several cellular 
processes, including proliferation, and thus are critical 
Figure 5: Tumors in Abcb4-/-/HBsAg+/- mice show histological characteristics of HCC. A. A representative H&E staining 
demonstrates well defined tumor borders (dashed line). B. Tumor stroma is nearly free from Sirius red staining fibrillar collagen. Arrows 
point out fibrotic area in surrounding liver tissue. C. Ki67 staining (arrows) demonstrates pronounced proliferation in tumor stroma. D. 
Type IV collagen immunostaining depicts a lack of expression inside tumor stroma. E. Immunostaining for glutamine synthetase depicts 
expression in pericentral hepatocytes (arrows) and diffuse expression pattern in tumor stroma. F. Immunostaining for HBsAg demonstrates 
the loss of transgene expression in tumors. L liver, T tumor. Magnification x100 A-F, scale bars 100μm.
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for HCC induction [35, 36]. It might be speculated that 
a simultaneous activation of these tumorigenic pathways 
is responsible for aggravated carcinogenesis in Abcb4-/-/
HBsAg+/- mice.
Interestingly, reduced HBsAg transgene 
expression barely had any effect on UPR and UPR 
induced apoptosis in Abcb4-/-/HBsAg+/- mice (compared 
to HBsAg controls). Reduced HBsAg accumulation and 
unchanged UPR induction is different to our previous 
observations, where loss of HBsAg expression by DNA 
methylation ameliorated cell stress and liver integrity 
in HBsAg+/- mice [37]. Animals with reduced HBsAg 
expression due to DNA methylation were excluded 
from the experiment in the current study. Furthermore, 
ER stress and UPR might play a role in Abcb4-/- mice, 
although CHOP and thereby ER stress dependent 
apoptosis were not induced (Figure 1C). Indeed, it has 
been described before that intrahepatic cholestasis due 
to accumulation of bile acids in the liver was associated 
with ER stress [38]. However, the cellular pathways that 
regulate the hepatic UPR and ER stress in cholestasis 
remain undefined [39]. The unfolded protein response 
(UPR) is generally activated in solid tumors and results 
in tumor cell anti-apoptosis and drug resistance [40]. On 
the other hand, it has been demonstrated that induction 
of ER-stress is essential for hepatocarcinogenesis [41]. 
A mouse model describing bile duct ligation combined 
with alpha-1 antitrypsin mutation PiZZ causing an ER 
storage disease has been published previously [42]. The 
authors concluded, that patients with α1-AT deficiency 
might be more susceptible to the development of 
severe liver disease when suffering from concomitant 
cholestatic liver injury and vice versa [42]. Our study 
confirms the conclusion that ER storage disease 
exacerbates cholestasis.
A limiting factor of our study might be a slight 
change of tumor incidence in the murine Abcb4-/- model 
during the last years. In a formerly published study we 
described 100% incidence of hepatic tumors in Abcb4-/-
 mice aged 52 weeks [43]. Hygienic housing conditions 
and analysis for the presence of mouse pathogens as well 
as subsequent therapy have been improved several times 
ever since in the animal facility. Influences of antibiotics 
regarding liver fibrosis and alterations of gut microbiota 
to hepatic fibrogenesis are well known [44, 45]. Thus 
reduction in HCC incidence over the years in Abcb4-/- 
mice are most likely caused by improvements of hygienic 
status [44, 45].
In summary we conclude that hepatic injury, 
caused by cholestasis and HBsAg induced storage 
disease, reflects a model of simultaneous liver damage 
with enhanced carcinogenesis. Our data suggest that 
concurrent biliary liver disease provides a ‘second-hit’ 
which enforces HBsAg-associated carcinogenesis by 
the potentiated activation of proto-oncogene cJun and 
STAT3.
MATERIALS AND METHODS
Animal experimentation
The present study was performed with permission 
of the State of Hesse, Regierungspraesidium Giessen, 
according to Section 8 of the German Law for the 
Protection of Animals and conforms to the NIH Guide 
for the Care and Use of Laboratory Animals. Transgenic 
mice were maintained at the Central Animal Laboratory 
of the Justus-Liebig-University Giessen under specified 
pathogen-free conditions. All experiments were approved 
by the Committee on the ethics of Animal Experiments 
of the Regierungspraesidium Giessen, Giessen, Germany 
(permit number: V54-19c 2015c GI20/10 Nr. A36/2011, 
Nr. A5/2012 and Nr. 52_2011).
BALB/c-Abcb4 mice (C.FVB(129P2)-Abcb4tm1Bor 
herein called Abcb4-/- mice) were bred and housed as 
described previously [22]. Characterization of Abcb4-/-  
genotype, sample collection, and routine analysis 
have been described elsewhere [22]. Generation and 
characteristics of transgenic lineages Tg(Alb-1HBV) 
(C57BL/6J-Tg (Alb1HBV) 44Bri/J) have been described 
[11]. These mice were backcrossed to BALB/cJ 
background (C.B6J-Tg (Alb1HBV) 44Bri N10 herein 
called HBsAg+/- mice) for 9 generations. HBsAg+/- mice 
were crossed with Abcb4-/- mice, resulting in the F2 
generation BALB/c-Abcb4/Alb1-HBV hybrid mice 
(C.Cg-Tg (Alb1HBV) 44Bri-Abcb4tm1Bor herein called 
Abcb4-/-/HBsAg+/- mice).
Mice were sacrificed at ages of 7-8 (young), 12-16 
(middle), and 52 weeks (old) (n=4-5 per age and sex). 
Livers were collected and underwent morphological 
diagnosis. Remaining samples were preserved for analyses 
as indicated. Serum samples were stored at −80°C until 
analysis of alanine aminotransferases (ALT), as well as 
alkaline phosphatase (AP) by routine clinical chemistry on 
a Reflotron Plus Analyzer (Roche, Mannheim, Germany).
Histology
Histology and immunohistochemistry were 
performed as described before [46]. Quantification of 
collagenous tissue was performed by assessment of stained 
area using ImageJ-software [11].
Immunohistochemistry
Immunohistochemistry was performed on 
paraffin sections (5 μm) by using ImmPRESS 
Peroxidase Detection Reagents (Vector Laboratories) 
and antibodies specific for HBsAg (monoclonal mouse 
antibody MA18/7) [47], Ki-67 (RM-9106-SO, Thermo 
Scientific, Dreieich, Germany), Typ IV collagen (10760, 
Progen, Heidelberg, Germany), glutamine synthetase 
(GTX 109121, GeneTex, Irvine, USA). The colour 
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reaction was carried out with VECTOR VIP Peroxidase 
Substrate Kit or DAB Peroxidase Substrate Kit, (Vector 
Laboratories).
Western blotting
Sample preparation, sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and Western blotting 
was performed as described before [48]. Total liver lysates 
were analyzed by using antibodies against HBsAg (20-
HR20, Fitzgerald, Acton, Ma, USA), phospho-PERK 
(16F8, Cell Signaling, Beverly, MA, USA), phospho-
eIF2α (119Α11, Cell Signaling), β-actin (13E5, Cell 
Signaling), c-Jun (60A8, Cell Signaling), phospho-c-Jun 
(D47G9, Cell Signaling), phospho-SAPK/JNK (81E11, 
Cell Signaling), STAT3 (79D7, Cell Signaling), phospho-
STAT3 (D3A7, Cell Signaling).
Bile acid analysis
Bile acids in serum were analyzed by UHPLC-MS/
MS essentially as described before [49].
Statistical analysis
Statistical analysis was performed with SPSS V.17.0 
(SPSS Inc.) and GraphPad Prism5 (GraphPas Software 
Inc). For non-normally distributed parameters, Mann-
Whitney U test and Spearman rank test were applied. 
Bivariate correlation of ALT and BA was performed with 
two tailed Spearman test. Enhanced tumor incidence was 
calculated with Chi2 statistics. The results are presented as 
mean ±SEM. *p<0.05 was considered significant.
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